GlassScriptPhysician profile
Aaron Jae Lee
NPI 1114246568
$111,123.46
in general payments reported to CMS, 2019-2025
32 companies · $28K in 2025
The $28K reported for 2025 was more than what 98% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $471 · 2021: $9,722 · 2022: $24K · 2023: $24K · 2024: $12K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $36K · Consulting Fee: $15K · Travel and Lodging: $8,213 · Food and Beverage: $4,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $36,000.00 |
| Consulting Fee | $15,190.00 |
| Travel and Lodging | $8,212.86 |
| Food and Beverage | $4,336.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $88,358.26 | 2019-2025 | Da Vinci Surgical System |
| Ethicon INC. | $14,407.85 | 2025 | |
| Medical Device Business Services, INC. | $2,416.47 | 2025 | |
| Ethicon US, LLC | $1,728.37 | 2019-2025 | Echelon Flex, Echelon Circular, Stratafix |
| Tela Bio, INC. | $1,610.12 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Integra Lifesciences Corporation | $484.65 | 2022-2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Aroa Biosurgery Incorporated | $460.31 | 2022-2025 | |
| Vioptix INC | $283.92 | 2023 | |
| Avanos Medical | $148.37 | 2019 | |
| Baxter Healthcare | $143.27 | 2022-2023 | Preveleak |
| Elucent Medical | $137.51 | 2025 | |
| Endogastric Solutions, INC | $125.70 | 2022 | |
| Karl Storz Endoscopy-America | $121.99 | 2020 | |
| Organogenesis INC. | $119.69 | 2024 | Puraply Wound Matrix |
| Tactile Systems Technology INC | $60.49 | 2025 | Nimbl, Flexitouch Plus |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $52.24 | 2021-2025 | Progrip |
| Allergan, INC. | $49.60 | 2019 | |
| Bard Peripheral Vascular, INC. | $46.90 | 2022-2023 | Venclose Maven Catheter |
| Innocoll Pharmaceuticals Limited | $45.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $44.38 | 2025 | Fasenra |
| Tersera Therapeutics LLC | $37.75 | 2024 | Xermelo |
| Takeda Pharmaceuticals U.S.A., INC. | $35.81 | 2024 | Iclusig |
| Pharmaessentia USA Corporation | $34.11 | 2024 | Besremi |
| Conmed Corporation | $33.33 | 2019 | |
| Abbvie INC. | $22.95 | 2020 | |
| Acell, INC. | $19.67 | 2020 | |
| Bk Medical Holding Company INC. | $18.08 | 2019 | |
| Braintree Laboratories, INC. | $15.90 | 2025 | Suflave, Sutab |
| Trevena, INC. | $15.39 | 2021 | |
| Silk Road Medical, INC. | $15.38 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Galvanize Therapeutics, INC | $15.29 | 2024 | Aliya System |
| Covidien LP | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.